Efficacy and Toxicity of Selinexor: Importance of Dose Intensity and Post Progression Outcomes скачать в хорошем качестве

Efficacy and Toxicity of Selinexor: Importance of Dose Intensity and Post Progression Outcomes

Dr. Efstathios Kastritis, National and Kapodistrian University of Athens, presents a summary real world evidence for the efficacy and clinical use of selinexor combinations, as well as the post-progression therapies and their outcome Background: Selinexor is the first in class, orally available, exportin inhibitor, approved for heavily pretreated, triple class refractory myeloma patients (pts) in combination with dexamethasone (Sd) and in pts with relapsed/refractory myeloma (RRMM) with 1-3 prior lines of therapy in combination with bortezomib and dexamethasone (SVd). In clinical practice, the use of selinexor is associated with gastrointestinal toxicity, appetite loss and fatigue which require aggressive management, and may limit its use, especially outside the context of a clinical trial. In this report we sought to provide “real world” evidence for the efficacy and clinical use of selinexor combinations, as well as the post-progression therapies and their outcome. Conclusions: In conclusion, outside the context of clinical trials, the efficacy of selinexor combinations in heavily pretreated RRMM pts is moderate, with responding pts having a higher probability for longer remissions. OS in this heavily pretreated population, however, exceeds 1 year and sets the benchmark for the evaluation of new therapies. Dose adjustments are required in most pts indicating that optimal dose of selinexor may be lower than the recommended. The prognostic impact of low serum albumin in these pts needs further evaluation as it may be a marker of poor nutrition, advanced disease and poor tolerance to selinexor. Authors: Efstathios Kastritis, MD, Panagiotis Malandrakis, MD, Vasiliki Spiliopoulou, MD, Ioannis Ntanasis-Stathopoulos, MD, Eirini Solia, Foteini Theodorakakou, MD, Rodanthi Syrigou, MD, Nikoletta-Aikaterini Kokkali, Magdalini Migkou, MD, Evangelos Eleutherakis Papaiakovou, MD, Despina Fotiou, MD, Maria Roussou, MD, Nikolaos Kanellias, MD, Maria Gavriatopoulou, MD, Evangelos Terpos, MD, PhD and Meletios A. Dimopoulos, MD ASH Abstract #3181: https://ash.confex.com/ash/2022/webpr... _______________ Improving Lives | Finding the Cure Founded in 1990, the International Myeloma Foundation (IMF) is the first and largest organization focusing specifically on multiple myeloma. The IMF’s reach extends to more than 525,000 members in 140 countries worldwide. The IMF is dedicated to improving the quality of lives of myeloma patients while working toward prevention and a cure through our four founding principles: Research, Education, Support, and Advocacy. Subscribe to our channel:    / imfmyeloma   Visit our website at: https://www.myeloma.org Find us online: Facebook: @myeloma |   / myeloma   Twitter: @IMFMyeloma |   / imfmyeloma   Instagram: @imfmyeloma |   / imfmyeloma   LinkedIn:   / international-myeloma-foundation   Support the IMF | Donate Now! https://secure.myeloma.org/page/40697... Category Nonprofits & Activism License Standard YouTube License In most cases, captions are autogenerated by YouTube.